In this study, doctors from Germany determined whether low-molecular-weight heparin can prevent acute post-ERCP pancreatitis.
The team randomized 448 patients who had an increased risk for acute post-ERCP pancreatitis to receive 1 of 2 treatments:
- Low-molecular-weight heparin (Certoparin 3000 IU subcutaneously).
- Or placebo (saline solution 0.3 mL subcutaneously) the day before ERCP.
The drug was given 2 hours before and 22 hours after ERCP.
The team recorded patient history, risks for acute post-ERCP pancreatitis, procedure-related data, pain, laboratory findings before and after ERCP, as well as post-ERCP complications.
The doctors found that both groups of patients were similar with regard to risks for acute post-ERCP pancreatitis and procedure-related data.
Overall, acute post-ERCP pancreatitis occurred in 9% of patients.
|Acute post-ERCP pancreatitis occurred in 9% of patients.|
The team determined that low-molecular-weight heparin did not reduce the frequency or severity of acute post-ERCP pancreatitis, compared to placebo.
Furthermore, the 24-hour serum amylase values and pain scores did not differ significantly between the low-molecular-weight heparin group and the placebo group.
There were 2 bleeding complications in the low-molecular-weight heparin group.
Dr Thomas Rabenstein and colleagues concluded, "Prophylactic subcutaneous administration of low-molecular-weight heparin does not prevent acute post-ERCP pancreatitis".